Ryan, something must come out before the Scarlett's presentation late this month!! I hope he announces his plan fro acquisition. If the news are welcome the SP may go up; otherwise, it will hit a low. If you are a confident investor, these things shouldn't matter to you since sooner or later the SP must seek its appropriate level to reflect IMET's success and company's enviable financial condition compared to a lot of other biotechs, including AST, BTX and even OCAT. I hope the responsible members of the Geron management show adequate foresight and wisdom keeping in view Geron shareholders' interest and not their bonus. opportunities!!.
The chart-following idiots do not need to know any of that stuff!! These monkeys just act like stupid animals in a herd!!
Bio, ways this board is infested heavily by idiotic shorts and day traders (lazy bums who are after only easy ways of making their living!) who do not have any knowledge of what is going on in the retinal science nor do they want to know more than what meager knowledge they may or may not have!! Look at the thumbdowns these vermin have given to your post which is not saying anything wrong. It is worthless to even make an attempt to add any thing to their empty brains!!
With that many on-going trials, it is foolish for some on this board to expect Janssen to give them weekly update on the MF trial!! Any such expectation should be from Scarlett as Greron has nothing else going on under its umbrella!!
This is w.r.t.telomere disorders and what causes those primarily; nothing to do with how to destroy cancer cells through telomere shrinkage. This shows that how far the developers of IMET at Geron had advanced while these ASH guys still hover around the preliminaries of the telomere science!! To me, this whole session is just a shock that why it takes these scientists that many years to realize since the Geron scientists and the Nobel-winning Elizabeth Blackburn had recognized importance of telomeres and telomerase. It is also shocking that how the hematologists have been brainwashed so far by the Jakafi guys that they did not have eyes or sense to look into this aspect of Oncology!! Therefore, your post is just a frustrating revelation to me!!
I think you have to ask Mayo guys about it!! I am sure they have been doing some kind of genetic study tying IMET efficacy.
The there won't be difference between me and the vermin!! I believe in living for doing something constructive and abhor liers, cheats and manipulators.
vermin attack every morning at the opening whereby vermin sell at high and then immediately place orders at much much lower bids. Is this a concerted effort by WS vermin or a bunch of easy-money seeking vermin? Hard to say!! But it's there!! These guys are a tumor of the market and the society who want to get rich quick through market manipulation and must have very low morale, as all easy-money-seeking vermin are!!
Side, I do not want to repeat what I already stated in my response earlier to-day but I do not think your "fear" is justified based on, of course, Tefferi's irrefutable work, publication in the NEJM, and JNJ's $1B conditional commitment. Of course, we must keep in mind that the Jakafi forces, Novartis/Incytes further trial using the modified form of Jakafi inhibitor, and use of Jakafi inhibitors in treatments performed at even Mayo make it more difficult to run with speed on the IMET trial. Also, I think, Jansssen must be very careful in selection of patients to be included in the trial, which must be taking longer than anticipated. I do not think all that means that there is some problem with IMET's effectiveness. If so, the FDA would not have granted it ODD.
Black, it's useless to communicate with any one who is so impervious and doesn't want to pay attention to what you really have to say. It is just a waste of effort. There are traders, shorts, "Chippy lovers", semi-pundits, and a few sensible ones who are in a silent mode visiting and posting on this board. My posts are generally for the benefit of the last group. Let the dogs bark, you just carry on what you believe is right.
I am talking of "any new" concern that may show up in the global testing of 100 patients. The sample at Mayo was for just 33 or so patients, I believe all from the USA.
Can you give me a reason why the SP is still dragged to below $3 level, especially if the investors know that the results from the trial by none other than Mayo Clinic (world's top facility) are great and that now it's Janssen which is involved fully in the IMET development with a commitment of $1B!! ? Why do they need any more proof? Yes, the traders do, just like the mon...keys are screaming about DILUTION!!
That will depend on the mix of patients the trial will use vis-a-vis those used by Tefferi. I think since the former uses a global sampling and availability, the results will most likely will not be the same. However, what the FDA will look for will be not the similarity in the results of the two investigations but the general confirmation that IMET does bring some CRs and PRs. Once the results are available, there will be an exhaustive study as to which genomic condition of patients respond well and which do not so that the prescribing physicians have proper guidance. Thus, this process is not going to be so fast; it can not be; and, most likely dragged on while the FDA may give license, because of "unmet" need then, if any, or as a perhaps better alternate to another approved treatment. Note that Janssen, or Janssen and Geron jointly, may continue further studies for other hematologic and solid-tumor applications. Therefore, I see a long-drawn out process for the whole thing. My view is that, for this reason, it will be wise if the Geron management to give up its idea of looking for acquisition and find ways for a profitable and decent merge with Janssen. Is Scarlett the right guy to do it? I have no confidence in him!!
He threw a monkey wrench and that's what has caused the problem for the current share-price action. Did he do it deliberately (like my dream story posted on this board yesterday) or not is the question I have in my mind!!
the ball is in Scarlett's court; he is holding it and neither Tefferi nor Janssen. The FDA had managed to throw it in the Janssen's court; but, Scarlett grabbed it when he announced the acquisition idea. Now all eyes must be on what he utters next when he opens his mouth and not on Janssen (because Janssen doesn't care what happens to Geron shareholders; its worry is to make sure that its $1B commitment bears fruit down the road!).
It is down not due to lack of new data, it's due to Scarlett's shut-mouth to let shareholders know what is he doing for the acquisition, especially if he is looking for his own interest there or shareholders'. Please do not remain in unnecessary illusion and digest the fact, instead of being blindly faithful to Geron management (which has their WS buddies' best interests at heart and not retail shareholders'!) It is your money and not Scarlett's. So, please wake up. That's what institutions are apparently doing before plunging in!!